Continued access to sutimlimab for cold agglutinin disease patients in japan
NCT ID NCT05132127
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study gave sutimlimab to 7 adults with cold agglutinin disease (CAD) who had already completed earlier studies and still needed treatment. The goal was to keep providing the drug until it became commercially available in Japan. Researchers tracked side effects and serious side effects to check safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLD AGGLUTININ DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 3920001
Tokyo, 113-8431, Japan
-
Investigational Site Number 3920002
Saitama, 350-0495, Japan
-
Investigational Site Number 3920003
Osaka, 565-0871, Japan
-
Investigational Site Number 3920004
Kanagawa, 259-1193, Japan
-
Investigational Site Number 3920005
Ishikawa, 920-8530, Japan
Conditions
Explore the condition pages connected to this study.